Late Stage Mature Pre IPO Unicorns - PreIPOSwap.com

Norovirus vaccine developer HilleVax upsizes proposed IPO to $175M

By Val Kennedy,    Novovirus vaccine developer HilleVax (HLVX) has upsized its initial public offering to $175M from $100M. The biotech company said in an amended filing on Monday that it now plans to offer 10.3M shares priced between $16 and $18 per share. If priced at the midpoint, the company would raise approximately $175M. In a filing[…]

Lung cancer test developer BioAffinity files for $19M IPO

By Val Kennedy,     BioAffinity Technologies (BIAF), which is developing a test to better detect lung cancer in its earliest stages, has filed for a $19M initial public offering. The Texas-based diagnostics maker didn’t specify the number of shares to be offered and their pricing, but indicated that it hoped to raise up to $19M through[…]